BridgeMD
Open-label Extension of KarXT + KarX-EC for Agitation in Alzheimer’s Disease
EU CTIS ID: 2024-519994-20-00
What this study is testing
To assess the long-term safety and tolerability of KarXT + KarX-EC in participants with agitation associated with AD.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- The participants who can participate in this study are those who have finished either study CN0120023 or CN0120024.
- Participants also must sign a new informed consent form and continue to have a caregiver who can continue to accompany them to all study visits, make sure they take their medication and follow the study rules, and agree to participate in interviews and questionnaires about the participant’s behavior (approximately 10 hours a week or more).
You likely can't join if
- Participants must not have clinically significant cardiovascular (eg, untreated or unstable hypertension, clinically significant tachycardia), pulmonary, renal, hematologic, GI, endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other condition that, in the opinion of the investigator, would jeopardize the safety of the participant or the validity of the study results.
The study team makes the final eligibility decision.
Where it's taking place
- Japan
- Mexico
- Korea, Republic of
- Argentina
- Ukraine
- United Kingdom
- Canada
- Israel
- United States
- Taiwan
- Brazil
- Chile
- India
- China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Japan; Mexico; Korea, Republic of; Argentina; Ukraine; United Kingdom and 8 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.